Botulinum Toxin Zonal Injection for Uniform Migraine Nerve Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FDA-approved methods for treating migraines using Botulinum toxin suffer from limited dosing and administration volume, leading to sporadic treatment coverage of sensory nerves and unwanted side effects such as muscle paralysis.
Innovation Solution
Administer higher total doses and larger volumes of Botulinum toxin extramuscularly to specific nerve clusters and exit points in the head and neck, targeting sensory nerves responsible for migraine symptoms while minimizing muscle paralysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher total doses and larger volumes of Botulinum toxin are administered extramuscularly to specific nerve clusters, then treatment coverage of sensory nerves is improved, but the risk of muscle paralysis increases
Solution Approach 1:
The patent applies local quality by targeting specific nerve clusters (frontal, temporal, occipital, cervical) with zone-specific dosing. Different regions receive different doses based on their anatomical characteristics and nerve density, allowing optimized sensory nerve coverage while avoiding excessive accumulation in muscle-rich areas that could cause paralysis.
Solution Approach 2:
The patent uses extramuscular injection as an intermediary approach, delivering Botulinum toxin to sensory nerves through fascial planes and nerve exit points rather than direct intramuscular injection. This intermediary pathway allows the toxin to reach sensory nerves effectively while bypassing the muscle tissue that would otherwise be directly affected, reducing paralysis risk.
2Reliability
If larger volumes of Botulinum toxin are administered to ensure uniform coverage of sensory nerves, then treatment efficacy is improved, but the total quantity of substance increases
Solution Approach 1:
The patent optimizes the distribution of Botulinum toxin by applying zone-specific dosing strategies. Each anatomical zone (frontal, temporal, occipital, cervical) receives a tailored volume based on its specific nerve density, fascial architecture, and clinical requirements, achieving uniform coverage without unnecessary accumulation in any single area.
Solution Approach 2:
The patent segments the head and neck region into distinct anatomical zones with separate injection sites and dosing protocols. This segmentation allows precise control over toxin distribution, ensuring each zone receives the appropriate volume for effective sensory nerve coverage while avoiding excessive total dosage through targeted delivery.
Data Source
Figure 1A~1B
Figure 2A
Figure 2B
AI summary
The present specification discloses methods and uses for treating a migraine disorder. The disclosed method comprising extramuscularly administering a Botulinum toxin to an individual in one of more areas of a fronto-fascial layer located in a frontal head region of the individual, one of more areas of a temporoparietal-fascial layer located in a temporal head region of the individual, and one or more areas of an occipito-fascial layer located in an occipital head region of the individual. The disclosed methods and uses further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points and/or one or more subcutaneous locations in the head and neck as well as one or more sites of an epicranial aponeurosis. The disclosed methods and uses further comprise intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitus muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.